Gilead Sciences, Inc.$130.81BMY · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B |
| Cost of Revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B |
| Gross Profit | — | — | — | — | — | $30.75B | $18.07B | $16.09B |
| Research & Development | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B |
| Selling, General & Administrative | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B |
| Operating Expenses | $38.87B | $56.68B | $36.57B | $38.45B | $38.29B | $49.39B | $21.17B | $16.59B |
| Interest Expense | — | — | $1.17B | $1.23B | $1.33B | $1.42B | $656.00M | $183.00M |
| Other Income / (Expense) | -$674.00M | -$893.00M | $1.16B | -$576.00M | $720.00M | $2.31B | -$938.00M | $854.00M |
| Income Before Taxes | $9.33B | -$8.38B | $8.44B | $7.71B | $8.10B | -$6.87B | $4.97B | $5.97B |
| Provision for Income Taxes | $2.27B | $554.00M | $400.00M | $1.37B | $1.08B | $2.12B | $1.51B | $1.02B |
| Net Income | $7.05B | -$8.95B | $8.03B | $6.33B | $6.99B | -$9.02B | $3.44B | $4.92B |
| Basic EPS | $3.47 | -$4.41 | $3.88 | $2.97 | $3.15 | -$3.99 | $2.02 | $3.01 |
| Diluted EPS | $3.46 | -$4.41 | $3.86 | $2.95 | $3.12 | -$3.99 | $2.01 | $3.01 |
| Basic Shares Outstanding | 2.03B | 2.03B | 2.07B | 2.13B | 2.22B | 2.26B | 1.71B | 1.63B |
| Diluted Shares Outstanding | 2.04B | 2.03B | 2.08B | 2.15B | 2.25B | 2.26B | 1.71B | 1.64B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $6.97 | $6.80 | $7.15 | 8 | ↑8 ↓0 |
| Dec 2027 | $6.35 | $5.84 | $7.32 | 13 | ↑7 ↓2 |
| Dec 2028 | $5.11 | $4.27 | $5.92 | 7 | ↑3 ↓2 |
| Dec 2029 | $4.53 | $3.46 | $5.59 | 4 | ↑1 ↓2 |
